StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Each factor shows CV's percentile within the scored universe — observational ranking, not a recommendation.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $7.29 | $7.15 | -1.92% | 0.1M |
| 05-13 | $7.11 | $7.00 | -1.55% | 0.1M |
| 05-14 | $6.94 | $7.30 | +5.19% | 0.1M |
| 05-15 | $6.50 | $6.46 | -0.69% | 0.1M |
| 05-18 | $6.50 | $6.36 | -2.15% | 0.1M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Finnhub hasn't published the next scheduled earnings date yet. The list typically populates 4–8 weeks before the call.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $2.79M | $13.55M | $9.64M | $6.10M |
Operating Income | $-7.09M | $-25.52M | $-18.05M | $-10.03M |
Net Income | $-7.03M | $-25.32M | $-17.92M | $-4.63M |
EPS (Diluted) | $-0.15 | $-1.03 | $-1.05 | $-4.49 |
Total Assets | $25.95M | $18.16M | $25.66M | $9.55M |
Total Liabilities | $5.72M | $4.90M | $5.22M | $4.91M |
Cash & Equivalents | Not available | Not available | Not available | Not available |
Free Cash Flow OCF − CapEx | $-6.11M | $-22.95M | $-15.26M | $-9.58M |
Shares Outstanding | 49.84M | 46.87M | 46.80M | 2.46M |
CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. CapsoVision's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D, directed at the large intestines. Geographically, the company generates the majority of its revenue from the United States.